An economic analysis of hormone replacement therapy for the prevention of fracture in young postmenopausal women

Expert Opinion on Pharmacotherapy

Volumn 4, Issue 9, 2003, Pages 1479-1488

  Lamy, Olivier ^a   Krieg, Marc Antoine ^a   Burckhardt, Peter ^a   Wasserfallen, Jean Blaise ^a  

^a LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

Author keywords

Effectiveness; Hormonal replacement therapy; Osteoporosis; Prevention; Young postmenopausal women

Indexed keywords

ALENDRONIC ACID; CALCITONIN; CALCIUM; CONJUGATED ESTROGEN PLUS MEDROXYPROGESTERONE ACETATE; ESTRADIOL; ESTROGEN; ETHINYLESTRADIOL; GESTAGEN; NORETHISTERONE ACETATE; PARATHYROID HORMONE; RALOXIFENE; RISEDRONIC ACID; VITAMIN D;

BREAST CANCER; CHOLECYSTITIS; CLINICAL TRIAL; COLORECTAL CANCER; CORONARY ARTERY DISEASE; COST CONTROL; COST EFFECTIVENESS ANALYSIS; DEMENTIA; DOSE RESPONSE; FEMALE; FRAGILITY FRACTURE; HEALTH CARE COST; HIGH RISK POPULATION; HORMONE SUBSTITUTION; HUMAN; META ANALYSIS; OSTEOLYSIS; OSTEOPENIA; POSTMENOPAUSE OSTEOPOROSIS; QUALITY OF LIFE; REVIEW; STROKE; THROMBOEMBOLISM;

AGE FACTORS; COST-BENEFIT ANALYSIS; ESTROGEN REPLACEMENT THERAPY; ESTROGENS; FEMALE; FRACTURES, BONE; HUMANS; OSTEOPOROSIS, POSTMENOPAUSAL; PROGESTINS; RANDOMIZED CONTROLLED TRIALS;

EID: 0141851878     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656566.4.9.1479     Document Type: Review

References (65)

1. WEISS NS, URE CL, BALLARD JH, WILLIAMS AR, DALING JR: Decreased risk of fractures of the hip and lower forearm with postmenopausal use of estrogen. N. Engl. J. Med. (1980) 303(21):1195-1198.
2. CAULEY JA, SEELEY DG, ENSRUD K, ETTINGER B, BLACK D, CUMMINGS SR: Estrogen replacement therapy and fractures in older women. Ann. Intern. Med. (1995) 122(1):9-16.
3. MAXIM P, ETTINGER B, SPITALNY GM: Fracture protection provided by long-term estrogen treatment. Osteoporosis Int. (1995) 5(1):23-29.
4. NELSON HD, RIZZO J, HARRIS E et al.: Study of Osteoporotic Fractures Research Group. Osteoporosis and fractures in postmenopausal women using estrogen. Arch. Intern. Med. (2002) 162(20):2278-2284.
5. ROSSOUW JE, ANDERSON GL, PRENTICE RL et al.: Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA (2002) 288(3):321-333.
6. MICHAELSSON K, BARON JA, FARAHMAND BY et al.: Hormone replacement therapy and risk of hip fracture: population based case-control study. The Swedish Hip Fracture Study Group. Br. Med. J. (1998) 316(7148):1858-1863.
7. NELSON HD, HUMPHREY LL, NYGREN P, TEUTSCH SM, ALLAN JD: Postmenopausal hormone replacement therapy: scientific review. JAMA (2002) 288(7):872-881.
8. HULLEY S, FURBERG C, BARRETT-CONNOR E et al.: Non cardiovascular disease outcomes during 6.8 years of hormone therapy: Heart and Estrogen/progestin Replacement Study follow-up (HERS II). JAMA (2002) 288(1):58-66.
9. GRADY D, HERRINGTON D, BITTNER V et al.: Cardiovascular disease outcomes during 6.8 years of hormone therapy: Heart and Estrogen/progestin Replacement Study follow-up (HERS II). JAMA (2002) 288(1):49-57.
10. US PREVENTIVE SERVICES TASK FORCE: Postmenopausal hormone replacement therapy for primary prevention of chronic conditions: recommendations and rationale. Ann. Intern. Med. (2002) 137(10):834-839.
11. ANONYMOUS: Consensus development conference. Diagnosis, prophylaxis and treatment of osteoporosis. Am. J. Med. (1991) 90(6):170-210.
12. KANIS JA, DELMAS P, BURCKHARDT P, COOPER C, TORGERSON D: Guidelines for diagnosis and management of osteoporosis. Osteoporosis Int. (1997) 7(4):390-406.
13. KANIS JA, ODEN A, JOHNELL O, JONSSON B, DE LAET C, DAWSON A: The burden of osteoporotic fractures: a method for setting intervention thresholds. Osteoporesis Int. (2001) 12(5):417-427.
14. NATIONAL OSTEOPOROSIS FOUNDATION OF THE US: Osteoporosis: review of the evidence for prevention, diagnosis and treatment and cost-effective analysis. Osteoperosis Int. (1998) 8(10):S7-S80.
15. RAY NF, CHAN JK, THAMER M, MELTON LJ 3rd: Medical expenditures for the treatment of osteoporotic fractures in the United States in 1995: report from the National Osteoporosis Foundation. J. Bone Miner. Res. (1997) 12(1):24-35.
16. CUMMINGS SR, BLACK DM, RUBIN SM: Lifetime risks of hips, Colles', or vertebral fracture and coronary heart disease among white postmenopausal women. Arch. Intern. Med. (1989) 149(11):2445-2448.
17. O'NEILL TW, FELSENBERG D, VARLOW J, COOPER C, KANIS JA, SIMAN AF: The prevalence of vertebral deformity in European men and women: the European Vertebral Osteroporsis Study. J. Bone Miner. Res. (1996) 11(7):1010-1018.
18. MELTON LJ 3rd, LANE AW, COOPER C, EASTELL R, O'FALLON WM, RIGGS BL: Prevalence and incidence of vertebral deformities. Osteoporosis Int. (1993) 3(3):113-119.
19. MEUNIER PJ AND BOIVIN G: Bone mineral density reflects bone mass but also the degree of mineralization of bone: therapeutic implications. Bone (1997) 21(5):373-377.
20. KANIS JA, MELTON LJ, CHRISTIANSEN C, JOHNSTON CC, KHALTAEV N: The diagnosis of osteoporosis. J. Bone Miner. Res. (1994) 9(8):1137-1141.
21. GULLBERG B, JOHNELL O, KANIS JA: World-wide projections for hip fracture. Osteoporosis Int. (1997) 7(5):407-413.
22. ADACHI JD, IOANNIDIS G, OLSZYNSKI WP et al.: The impact of incident vertebral and non-vertebral fractures on health related quality of life in postmenopausal women. BMC Musculoskelet. Disord (2002) 3(1):11.
23. FINK HA, ENSRUD KE, NELSON DB et al.: Disability after clinical fracture in postmenopausal women with low bone density: the fracture intervention trial (FIT). Osteoporosis Int. (2003) 14(1):69-76.
24. CUDDIHY MT, GABRIEL SE, CROWSON CS, O'FALLON WM, MELTON LJ 3rd: Forearm fractures as predictors of subsequent osteoporotic fractures. Osteoporosis Int. (1999) 9(6):469-475.
25. MELTON LJ 3rd, ATKINSON EJ, COOPER C, O'FALLON WM, RIGGS BL: Vertebral fractures predict subsequent fractures. Osteoporosis Int. (1999) 10(3):214-221.
26. BLACK DM, ARDEN NK, PALERMO L, PEARSON J, CUMMINGS SR: Prevalent vertebral deformities predict hip fractures and new vertebral deformities but not wrist fractures. Study of Osteoporotic Fractures Research Group. J. Bone Miner. Res. (1999) 14(5):821-828.
27. ROSS PD, DAVIS JW, EPSTEIN RS, WASNICH RD: Pre-existing fractures and bone mass predict vertebral fracture incidence in women. Annals Int. Med. (1991) 114(11):919-923.
28. KANIS JA, JOHNELL O, ODEN A, DAWSON A, DE LAET C, JONSSON B: Ten year probabilities of osteoporotic fractures according to BMD and diagnostic thresholds. Osteoperosis Int. (2001) 12(12):989-995.
29. GENANT HK, LUCAS J, WEISS S et al.: Low-dose esterified estrogen therapy: effects on bone, plasma estradiol concentrations, endometrium, and lipid levels. Estratab/Osteoporosis Study Group. Arch. Intern. Med. (1997) 157(22):2609-2615.
30. ETTINGER B, GENANT HK, STEIGER P, MADVIG P: Low-dosage micronized 17 beta-estradiol prevents bone loss in postmenopausal women. Am. J. Obstet. Gynecol. (1992) 166(2):479-488.
31. WEISS SR, ELLMAN H, DOLKER M: A randomized controlled trial of four doses of transdermal estradiol for preventing postmenopausal bone loss. Transdermal Estradiol Investigator Group. Obstet. Gynecol. (1999) 94(3):330-336.
32. SPEROFF L, ROWAN J, SYMONS J, GENANT H, WILBORN W. The comparative effect on bone density, endometrium, and lipids of continuous hormones as replacement therapy (CHART study). A randomized controlled trial. JAMA (1996) 276(17):1397-1403.
33. WELLS G, TUGWELL P, SHEA B et al.: Meta-analyses of therapies for postmenopausal osteoporosis. V. Meta-analysis of the efficacy of hormone replacement therapy in treating and preventing osteoporosis in postmenopausal women. Endocr. Rev. (2002) 23(4):529-539.
34. HULLEY S, GRADY D, BUSH T et al.: Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/progestin Replacement Study (HERS) Research Group. JAMA (1998) 280(7):605-613.
35. TORGERSON DJ, BELL-SYER SE: Hormone replacement therapy and prevention of nonvertebral fractures: a meta-analysis of randomized trials. JAMA (2001) 285(22):2891-2897.
36. CAULEY JA, ZMUDA JM, ENSRUD KE, BAUER DC, ETTINGER B: Timing of estrogen replacement therapy for optimal osteoporosis prevention. J. Clin. Endocrinol. Metab. (2001) 86(12):5700-5705.
37. KIEL DP, FELSON DT, ANDERSON JJ, WILSON PW, MOSKOWITZ MA: Hip fracture and the use of estrogens in postmenopausal women. The Framingham Study. N. Engl. J. Med (1987) 317(19):1169-1174.
38. HAYS J, OCKENE JK, BRUNNER RL et al.: Effects of estrogen plus progestin on health-related quality of life. N. Engl. J. Med. (2003) 348(19):1839-1854.
39. GRODSTEIN F. NEWCOMB PA, STAMPFER MJ: Postmenopausal hormone therapy and the risk of colorectal cancer: a review and meta-analysis. Am. J. Med. (1999) 106(5):574-582.
40. MILLER J, CHAN BK, NELSON HD: Postmenopausal estrogen replacement and risk for venous thromboembolism: a systematic review and meta-analysis for the US Preventive Services Task Force. Ann. Intern. Med. (2002) 136(9):680-690.
41. LACEY JV Jr, MINK PJ, LUBIN JH et al.: Menopausal hormone replacement therapy and risk of ovarian cancer. JAMA (2002) 288(3):334-341.
42. ETTINGER B, BLACK DM, MITLAK BH et al.: Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators. JAMA (1999) 282(7):637-645.
43. CHESNUT CH, SILVERMAN S, ANDRIANO K et al.: A randomized trial of nasal spray calcitonin in postmenopausal women with established osteoporosis: the recurrence of osteoporotic fractures study. PROOF Study Group. Am. J. Med. (2000) 109(4):267-276.
44. LIBERMAN UA, WEISS SR, BROLL J et al.: Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. N. Engl. J. Med. (1995) 333(22):1437-1443.
45. HARRIS ST, WATTS NB, GENANT HK et al.: Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomised controlled trial. Vertebral Efficacy With Risedronate Therapy (VERT) Study Group. JAMA (1999) 282(14):1344-1352.
46. NEER RM, ARNAUD CD, ZANCHETTA JR et al.: Effect of parathyroid hormone (1-34) on fiactures and bone mineral density in postmenopausal women with osteoporosis. N. Engl. J. Med. (2001) 344(19):1434-1441.
47. BLACK DM, THOMPSON DE, BAUER DC et al.: Fracture Intervention Trial. Fracture risk reduction with alendronate in women with osteoporosis: the Fracture Intervention Trial. FIT Research Group. J. Clin. Endocrinol. Metab. (2000) 85(11):4118-4124.
48. MCCLUNG MR, GEUSENS P, MILLER PD et al.: Hip Intervention Program Study Group. Effect of risedronate on the risk of hip fracture in elderly women. Hip Intervention Program Study Group. N. Engl. J. Med. (2001) 344(5):333-340.
49. LAMY O, KRIEG MA, BURCKHARDT P: Treatment indications for osteoporosis. Rev. Med. Suisse Romande (2002) 122(8):383-387.
50. HOSKING D, CHILVERS CE, CHRISTIANSEN C et al.: Prevention of bone loss with alendronate in postmenopausal women under 60 years of age. Early Postmenopausal Intervention Cohort Study Group. N. Engl. J. Med. (1998) 338(8):485-492.
51. MORTENSEN L, CHARLES P, BEKKER PJ, DIGENNARO J, JOHNSTON CC Jr: Risedronate increases bone mass in an early postmenopausal population: two years of treatment plus one year of follow-up. J. Clin. Endocrinol. Metab. (1998) 83(2):396-402.
52. CHRISCHILLES E, SHIREMAN T, WALLACE R. Costs and health effects of osteoporotic fractures. Bone (1994) 15(4):377-386.
53. DOLAN P, TORGERSON DJ: The cost of treating osteoporotic fractures in the United Kingdom female population. Osteoporosis Int. (1998) 8(6):611-617.
54. TOSTESON AN, GABRIEL SE, GROVE MR, MONCUR MM, KNEELAND TS, MELTON LJ 3rd: Impact of hip and vertebral fractures on quality-adjusted life years. Osteoporosis Int. (2001) 12(12):1042-1049.
55. OLEKSIK A, LIPS P, DAWSON A, MINSHALL ME et al.: Health-related QOL in postmenopausal women with low BMD with or without prevalent vertebral fractures. J. Bone Miner. Res. (2000) 15(7):1384-1392.
56. GABRIEL SE, KNEELAND TS, MELTON LJ 3rd, MONCUR MM, ETTINGER B, TOSTESON AN: Health-related QOL in economic evaluations for osteoporosis : whose values should we use? Med. Decis. Making (1999) 19(2):141-148.
57. SALKELD G, CAMERON ID, CUMMING RG et al.: QOL related to fear of falling and hip fracture in older women: a time trade off study. Br. Med. J. (2000) 320(7231):341-346.
58. GOLDMAN L, WEINSTEIN MC, GOLDMAN PA, WILLIAMS LW: Cost-effectiveness of HMG-CoA reductase inhibition for primary and secondary prevention of coronary heart disease. JAMA (1991) 265(9):1145-1151.
59. TOSTESON AN, GABRIEL SE, KNEELAND TS, MONCUR MM, MANGANIELLO PD, SCHIFF I: Has the impact of hormone replacement therapy on health-related QOL been undervalued? J. Women Health Gend. Based Med. (2000) 9(2):119-130.
60. ZETHRAEUS N, SEDRINE WB, CAULIN F, CORCAUD S: Models for assessing the cost-effectiveness of the treatment and prevention of osteoporosis. Osteoporosis Int. (2002) 13(11):841-857.
61. FLEURENCE R, TORGERSON DJ, REID DM: Cost-effectiveness of hormone replacement therapy for fracture prevention in young postmenopausal women: an economic analysis based on a prospective cohort study. Osteoporosis Int. (2002) 13(8):637-643.
62. TOSTESON AN, ROSENTHAL DI, MELTON LJ, WEINSTEIN MC: Cost effectiveness of screening perimenopausal white women for osteoporosis: bone densitometry and hormone replacement therapy. Ann. Intern. Med. (1990) 113(8):594-603.
63. KANIS JA, BRAZIERJE, STEVENSON M, CALVERT NW, LLOYD JONES M: Treatment of established osteoporosis: a systematic review and cost-utility analysis. Health Technol. Assess. (2002) 6(29):1-256.
64. WILLIS MS: The health economics of calcium and vitamin D3 for the prevention of osteoporotic hip fractures in Sweden. Int. J. Technol. Assess. Health Care (2002) 18(4):791-807.
65. GRADY D: Postmenopausal hormones - therapy for symptoms only. N. Engl. J. Med (2003) 348(19):1835-1837.